Table 6

Panel expressions of combining at least two immunostains in endocervical and endometrial adenocarcinomas.

ECA

EMMA

p-value


MUC1* & P16

MUC1+, P16-

0 (0%)

10 (100%)

0.001

MUC1-, P16+

8 (100%)

0 (0%)

MUC1 & VIM

MUC1+, VIM+

1 (7.7%)

9 (69.2%)

0.004

MUC1-, VIM-

12 (92.3%)

4 (30.8%)

MUC1 & ER

MUC1+, ER+

0 (0%)

13 (100%)

0.001

MUC1-, ER-

9 (100%)

0 (0%)

MUC1 & PR

MUC1+, PR+

0 (0%)

12 (72.2%)

0.001

MUC1-, PR-

9 (100%)

0 (27.8%)

P16 & VIM

P16-, VIM+

0 (0%)

7 (77.8%)

0.002

P16+, VIM-

9 (100%)

2 (22.2%)

P16 & ER

P16-, ER+

1 (11.1%)

14 (93.3%)

0.001

P16+, ER-

8 (88.9%)

1 (6.7%)

P16 & PR

P16-, PR+

2 (18.2%)

13 (92.9%)

0.001

P16+, PR-

9 (81.8%)

1 (7.1%)

VIM & ER

VIM+, ER+

0 (0%)

9 (90%)

0.001

VIM-, ER-

10 (100%)

1 (10%)

VIM & PR

VIM+, PR+

0 (0%)

8 (88.9%)

0.001

VIM-, PR-

10 (100%)

1 (11.1%)

ER & PR

ER+, PR+

2 (16.7%)

15 (100%)

0.001

ER-, PR-

10 (83.3%)

0 (0%)

MUC1, ER & PR

MUC1+, ER+, PR+

0 (0%)

11 (100%)

0.001

MUC1-, ER-, PR-

8 (100%)

0 (0%)


ECA, endocervical adenocarcinoma; EMMA, endometrial mucinous adenocarcinoma. * Apical and cytoplasmic MUC1 expression.

Khoury et al. BMC Clinical Pathology 2006 6:1   doi:10.1186/1472-6890-6-1

Open Data